Despite the expectation that targeting XBP1 would accelerate disease progression, conditional genetic deletion of XBP1 in the CNS protects against experimental amyotrophic lateral sclerosis (ALS) [15]. Here, XBP1 is linked to amyotrophic lateral sclerosis.